However, it did not yield significant improvements in pain perception.[64] GLP-1 receptors have also been detected in the choroid plexus, and in a rodent model, their activation was shown to reduce cerebrospinal fluid secretion and intracranial pressure (ICP).[65] In patients with idiopathic intracranial hypertension (IIH) and obesity, exenatide, semaglutide, liraglutide have been associated with a reduction in the number of headache days, and exenatide significantly reduced ICP.[66, 67] Furthermore, animal studies have indicated potential benefits of GLP-1RAs in neuropathic pain and diabetic neuropathy, although clinical evidence remains inconsistent.[64] One study reported structural improvements in the nerves of patients with diabetic neuropathy receiving semaglutide or dulaglutide, while two other studies found no significant benefit in neuropathy symptoms with liraglutide and exenatide.[6870] Additional off-label uses under investigation include neurodegenerative disorders, polycystic ovary syndrome (PCOS), and osteoporosis
FanXZhouJBiXLiangJLuSYanXet alL-theanine suppresses the metastasis of prostate cancer by downregulating MMP9 and Snail
Best for: General nutrient repletion, fatigue, migraines, post-illness recovery Cellular Energy NAD+ IV NAD+ is a coenzyme central to cellular energy production and DNA repair
When it comes to fats, concentrated sources of polyunsaturated fats are not well tolerated at the quantities of fat consumed in a KD, with increased gastrointestinal complaints
However, the medications' effects on appetite and food intake may lead to reduced overall nutrient consumption, which is actually part of their intended mechanism for weight management
Liao X, Deng T, Zhu Y, Du G, Chen J
